MET and neoplasm: A potential broadly applicable approach for improving the therapeutic window for ADCs targeting antigens that are endogenously expressed in normal tissues, such as MET, involves decreasing specific ADC uptake in non-tumor tissue by reducing the mAb binding affinity to the target.